MAM
CBAY icon

Myriad Asset Management’s Cymabay Therapeutics CBAY Stock Holding History

Myriad Asset Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$93K Hold
30,000
– – 0.01% 65
2021
Q4 		$101K Hold
30,000
– – 0.01% 125
2021
Q3 		$110K Buy
+30,000
New +$118K 0.01% 138

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

Myriad Asset Management's CBAY Position: Q1 2022 in Review

Myriad Asset Management held its Cymabay Therapeutics (CBAY) position steady in Q1 2022 at 30,000 shares worth $93K. The position accounts for 0.01% of the portfolio, ranked #65.

Myriad Asset Management first reported a position in CBAY in Q3 2021 and has held it in 3 quarters since. The position peaked at $110K in Q3 2021. 118 funds tracked by Wall St. Rank hold CBAY as of Q1 2022.

  • Myriad Asset Management held 30,000 shares of Cymabay Therapeutics worth $93K as of Q1 2022.
  • Myriad Asset Management left its Cymabay Therapeutics share count unchanged in Q1 2022.
  • Cymabay Therapeutics made up 0.01% of Myriad Asset Management's portfolio in Q1 2022, its #65 holding.
  • Myriad Asset Management first reported a position in Cymabay Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • Myriad Asset Management's Cymabay Therapeutics position peaked at $110K in Q3 2021.
  • 118 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2022.

Based on Myriad Asset Management's 13F filing for Q1 2022, filed 16 May 2022.